Jia GD - Search Results

1

Whether Primary Bone-Only Oligometastatic Nasopharyngeal Carcinoma Patients Benefit From Radiotherapy to the Bones on the Basis of Palliative Chemotherapy Plus Locoregional Radiotherapy?-A Large-Cohort Retrospective Study.

Guo WP, Jia GD, Xie SY, Yu X, Meng XH, Tang LQ, Li XY, Luo DH. Guo WP, et al. Among authors: jia gd. Cancer Med. 2024 Nov;13(21):e70315. doi: 10.1002/cam4.70315. Cancer Med. 2024. PMID: 39494716 Free PMC article.

2

Intensive Local Radiotherapy Is Associated With Better Local Control and Prolonged Survival in Bone-Metastatic Nasopharyngeal Carcinoma Patients.

Li XY, Jia GD, Sun XS, Guo SS, Liu LT, Liu SL, Yan JJ, Luo DH, Sun R, Guo L, Mo HY, Tang LQ, Chen QY, Mai HQ. Li XY, et al. Among authors: jia gd. Front Oncol. 2020 Mar 20;10:378. doi: 10.3389/fonc.2020.00378. eCollection 2020. Front Oncol. 2020. PMID: 32266152 Free PMC article.

3

Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinoma.

Sun XS, Liang YJ, Jia GD, Liu SL, Liu LT, Guo SS, Sun R, Luo DH, Chen QY, Tang LQ, Mai HQ. Sun XS, et al. Among authors: jia gd. Oral Oncol. 2020 Jul;106:104711. doi: 10.1016/j.oraloncology.2020.104711. Epub 2020 Apr 13. Oral Oncol. 2020. PMID: 32298996

4

Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [¹⁸ F]-fluorodeoxyglucose positron emission tomography.

Xie HJ, Yu YF, Sun XS, Jia GD, Luo DH, Sun R, Liu LT, Guo SS, Liu SL, Chen QY, Tang LQ, Mai HQ. Xie HJ, et al. Among authors: jia gd. Cancer Med. 2020 Dec;9(23):8852-8863. doi: 10.1002/cam4.3500. Epub 2020 Oct 9. Cancer Med. 2020. PMID: 33034945 Free PMC article.

5

Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.

Yang JH, Sun XS, Xiao BB, Liu LT, Guo SS, Liang JD, Jia GD, Tang LQ, Chen QY, Mai HQ. Yang JH, et al. Among authors: jia gd. BMC Cancer. 2021 May 11;21(1):534. doi: 10.1186/s12885-021-08246-0. BMC Cancer. 2021. PMID: 33975558 Free PMC article.

6

Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA.

Liu LT, Liang YJ, Guo SS, Xie Y, Jia GD, Wen DX, Tang LQ, Chen QY, Mai HQ. Liu LT, et al. Among authors: jia gd. Head Neck. 2022 Jan;44(1):34-45. doi: 10.1002/hed.26897. Epub 2021 Oct 12. Head Neck. 2022. PMID: 34636116

7

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.

Li XY, Luo DH, Guo L, Mo HY, Sun R, Guo SS, Liu LT, Yang ZC, Yang JH, Qiu F, Sun XS, Wang P, Liu Q, Li JB, Tang QN, Lin C, Yang Q, Liu SL, Liang YJ, Jia GD, Wen DX, Guo CY, Yan JJ, Zhao C, Chen QY, Tang LQ, Mai HQ. Li XY, et al. Among authors: jia gd. J Clin Oncol. 2022 Apr 10;40(11):1163-1173. doi: 10.1200/JCO.21.01467. Epub 2022 Jan 6. J Clin Oncol. 2022. PMID: 34990291 Clinical Trial.

8

EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma.

Yuan L, Li S, Chen Q, Xia T, Luo D, Li L, Liu S, Guo S, Liu L, Du C, Jia G, Li X, Lu Z, Yang Z, Liu H, Mai H, Tang L. Yuan L, et al. Cell Death Differ. 2022 Aug;29(8):1513-1527. doi: 10.1038/s41418-022-00939-8. Epub 2022 Feb 1. Cell Death Differ. 2022. PMID: 35105963 Free PMC article.

9

Clinical characteristics and prognostic factors affecting survival after radical radiotherapy for early and late post-treatment metastatic nasopharyngeal carcinoma.

Jia GD, Sun XS, Li XY, Liu SL, Yang JH, Chen QY, Yuan L, Mai HQ. Jia GD, et al. BMC Cancer. 2023 Jan 3;23(1):7. doi: 10.1186/s12885-022-10494-7. BMC Cancer. 2023. PMID: 36597072 Free PMC article.

10

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.

Liu LT, Liu H, Huang Y, Yang JH, Xie SY, Li YY, Guo SS, Qi B, Li XY, Chen DP, Jin F, Sun XS, Yang ZC, Liu SL, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Qiu F, Yang Q, Liang YJ, Jia GD, Wen DX, Yan JJ, Zhao C, Chen QY, Sun R, Tang LQ, Mai HQ. Liu LT, et al. Among authors: jia gd. Lancet Oncol. 2023 Jul;24(7):798-810. doi: 10.1016/S1470-2045(23)00232-2. Epub 2023 Jun 5. Lancet Oncol. 2023. PMID: 37290468 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters